Oncology Venture receives response from the FDA to the IND-application and proposed pivotal study for LiPlaCis

NEXT STORY
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
PREV STORY
Vical and Brickell Announce Merger Agreement
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021

author_avatar
NASDAQ Market News

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

author_avatar
NASDAQ Market News

Orion and Propeller Health partner to bring new digital medicines to people with asthma and COPD

Orion Corporation                                  Press release  11 February 2019 at 4.00 p.m. EET Orion and Propeller ...

author_avatar
NASDAQ Market News